Ampicillin + cloxacillin


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult: PO Susceptible infections Per cap contains ampicillin 250 mg and cloxacillin 250 mg: 1 cap 4 times/day. Severe: Up to 12 caps/day. IM Moderate to severe infections Per inj contains ampicillin 125 mg and cloxacillin 125 mg: 1 inj 6 hrly. Severe: 2-4 inj 6 hrly. IV Susceptible infections Per inj contains ampicillin 250 mg and cloxacillin 250 mg: 1-2 inj 6 hrly.
Contraindications
Penicillin allergy.
Special Precautions
Allergy to cephalosporins, infectious mononucleosis, neonates with jaundice, history of convulsions, lactation.
Adverse Reactions
G.I.disturbances, pruritus, urticaria, erythema, exfoliative dermatitis, rashes, fever, joint pain, eosinophilia, bronchial asthma, angioneuratic oedema, hemolytic anaemia, serum sickness, CNS effects like hyperactivity, agitation, insomnia, anxiety, behavioural changes, confusion, dizziness and convulsions.
Potentially Fatal: Anaphylactic reaction.
Drug Interactions
Failure of oral contraceptives, increased rash with allopurinol, reduced bactericidal activity with chloramphenicol, erythromycin and tetracyclines.
CIMS Class
ATC Classification
J01CF02 - cloxacillin ; Belongs to the class of beta-lactamase resistant penicillins. Used in the systemic treatment of infections.
J01CA01 - ampicillin ; Belongs to the class of penicillins with extended spectrum. Used in the systemic treatment of infections.
S01AA19 - ampicillin ; Belongs to the class of antibiotics. Used in the treatment of eye infections.
Disclaimer: This information is independently developed by CIMS based on ampicillin + cloxacillin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in